Can US Scientists Uncover the Potential of an Antibody Against Long Covid?
Click to start listening
Synopsis
US scientists are launching a groundbreaking clinical trial to test the potential of a long-acting antibody, sipavibart, in treating Long Covid, a debilitating condition affecting millions worldwide. With over 200 symptoms, the trial aims to provide hope for effective treatments that can improve the lives of those suffering from this challenging health issue.
Key Takeaways
- Long Covid affects at least 65 million people globally.
- Over 200 symptoms are associated with Long Covid.
- The clinical trial involves 100 patients and aims to improve health outcomes.
- Sipavibart is a monoclonal antibody developed by AstraZeneca.
- The trial has received FDA approval and is part of a broader effort to tackle Long Covid.
New Delhi, May 3 (NationPress) A team of US researchers is embarking on a clinical trial to investigate the effectiveness of a long-lasting antibody aimed at combating Long Covid—a condition impacting approximately 65 million individuals globally.
This condition arises post-infection with the SARS-CoV-2 virus and is characterized by an array of over 200 symptoms that are not yet clearly defined.
The collaborative effort between Nova Southeastern University (NSU) and the Schmidt Initiative for Long Covid (SILC) has led to the initiation of a clinical trial focused on evaluating the safety and effectiveness of sipavibart, a long-acting monoclonal antibody developed by the British pharmaceutical company AstraZeneca.
The trial has enrolled 100 patients and has received approval from the FDA earlier this year. The primary objective is to alleviate symptoms associated with Long Covid and facilitate a return to full health.
“Long Covid presents a complex challenge with numerous symptoms, making it poorly understood,” commented Nancy Klimas, director of the Institute for Neuro-Immune Medicine at NSU.
“Securing an effective treatment could be transformative for those grappling with the diverse symptoms of Long Covid,” she further stated.
The study will analyze the efficacy of sipavibart, which has been approved in Japan and the EU for pre-exposure prophylaxis against Covid-19, in treating Long Covid. This trial forms part of three anticipated Long Covid treatment trials set to commence in 2025.
“With at least 65 million individuals affected globally and a spectrum of over 200 symptoms, the health consequences of this condition can be severe,” remarked Dr. John Redd, CEO of SILC.
“This trial reflects our overarching commitment to tackling the most urgent health challenges we face today. We are utilizing our research capabilities to potentially revolutionize treatment options for millions afflicted by Long Covid, thereby enhancing knowledge and improving patient outcomes through pioneering clinical research,” added Dr. Ken Dawson-Scully, NSU’s senior vice president for research and associate provost.
Point of View
I recognize the urgency of addressing Long Covid, a condition that has emerged as a significant health crisis affecting millions worldwide. The commitment of researchers to explore potential treatments reflects a broader dedication to public health and the need for innovative solutions. Any progress in understanding and treating Long Covid could have profound implications for individuals and healthcare systems alike.
NationPress
18/06/2025
Frequently Asked Questions
What is Long Covid?
Long Covid is a condition that persists after an initial Covid-19 infection, characterized by a variety of symptoms that can last for months or even years.
How many people are affected by Long Covid?
It is estimated that at least 65 million people worldwide are affected by Long Covid.
What is sipavibart?
Sipavibart is a long-acting monoclonal antibody developed by AstraZeneca, which is being tested for its effectiveness in treating Long Covid.
Who is leading the clinical trial?
The clinical trial is being conducted by researchers from Nova Southeastern University and the Schmidt Initiative for Long Covid.
What is the goal of the trial?
The trial aims to assess the safety and effectiveness of sipavibart in alleviating symptoms of Long Covid and improving patient health outcomes.
